MAP
TCRR

Moody Aldrich Partners’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Moody Aldrich Partners’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-124,062
Closed -$2.04M – 188
2021
Q2 		$2.04M Sell
124,062
-1,578
-1% -$31.9K 0.29% 95
2021
Q1 		$2.77M Buy
125,640
+2,001
+2% +$54.6K 0.4% 83
2020
Q4 		$3.82M Buy
+123,639
New +$3.13M 0.62% 76

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Moody Aldrich Partners's TCRR Position: Q3 2021 in Review

Moody Aldrich Partners sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 124,062 shares — an estimated $2.04M sold.

Moody Aldrich Partners first reported a position in TCRR in Q4 2020 and held it in 3 quarters. The position peaked at $3.82M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Moody Aldrich Partners reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Moody Aldrich Partners sold 124,062 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $2.04M.
  • Moody Aldrich Partners first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Moody Aldrich Partners's TCR2 Therapeutics Inc. Common Stock position peaked at $3.82M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Moody Aldrich Partners's 13F filing for Q3 2021, filed 29 Oct 2021.